Bioinformatics Market by Offerings (Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)), Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031

Market Size
$18.63B
MARKET SIZE, 2026
Projected Market Size
$34.41B
MARKET SIZE, 2031
CAGR
13.1%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

BIOINFORMATICS MARKET SIZE, SHARE & GROWTH SNAPSHOT

bioinformatics Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global bioinformatics market is projected to grow from USD 18.63 billion in 2026 to USD 34.41 billion by 2031, at a CAGR of 13.1% during the forecast period. The market was valued at USD 16.70 billion in 2025. This growth is driven by rising adoption of NGS technology, increasing incorporation of artificial intelligence and machine learning in biological data analysis, increased investment in precision medicine and omics research, and high demand for cloud-based bioinformatics tools. Growth in the bioinformatics market is also attributed to growing R&D activities in the pharmaceutical and biotechnology sector, increased application of bioinformatics in drug discovery, biomarker detection, and clinical trials, and the need to manage big biological data.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 16.70 Billion
    Current Market Size (2026): USD 18.63 Billion
    Forecast Market Size (2031): USD 34.41 Billion
    CAGR (2026–2031): 13.1%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest market share of 42.2% in 2025.
    Fastest-Growing Offering: Bioinformatics services are projected to register the highest CAGR of 14.8% during the forecast period.
    Fastest-Growing Technology: Multi-omics integration is projected to register the highest CAGR during the forecast period.
    Application Leader: Drug discovery & development accounted for the largest market share of 34.0% in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Leading companies include Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN N.V., and Agilent Technologies, Inc., which continue to strengthen their market positions through product innovation and expanding solution portfolios.
    Emerging companies such as DEEP GENOMICS and DNASTAR have established strong positions in specialized niche areas, highlighting their potential as future market leaders.

The bioinformatics market is driven by the increased adoption of next-generation sequencing (NGS) technology, greater funding for genomics and precision medicine, and high demand for faster, large-scale biological data analysis. Moreover, the growing deployment of bioinformatics tools by pharmaceutical and biotech firms, clinical laboratories, hospitals, and research organizations for applications such as drug discovery, biomarker discovery, clinical genomics, and multi-omics studies is fueling the market by enhancing research efficiency and clinical decision-making.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

There are major changes taking place in the bioinformatics industry, driven by advances in genomics, artificial intelligence (AI), and cloud technology, which have revolutionized biological data analysis and life science research. Next-generation sequencing (NGS), the rise of precision medicine, and the use of bioinformatics in drug discovery, biomarker discovery, and clinical genomics are among the factors fueling market growth. With the help of AI and machine learning technologies, bioinformatics solutions have become capable of analyzing large biological datasets rapidly and precisely, whereas cloud-based systems help with better data management and collaboration.

bioinformatics Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing adoption of Next-Generation Sequencing (NGS)
  • Growing demand for personalized medicine
RESTRAINTS
Impact
Level
  • High cost of bioinformatics infrastructure
  • Data privacy, security, and regulatory compliance concerns
OPPORTUNITIES
Impact
Level
  • Expansion of clinical bioinformatics
  • Adoption of cloud and federated bioinformatics platforms
CHALLENGES
Impact
Level
  • Management of large data volumes
  • Lack of interoperability and multiplatform capabilities

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing adoption of Next-Generation Sequencing (NGS)

The growing prevalence of next-generation sequencing (NGS) technology is another important driver of the global bioinformatics market. Compared with conventional sequencing technologies, NGS enables fast, low-cost sequencing of DNA and RNA. In addition to advances in sequencing technologies, there is an exponential increase in genomics, transcriptomics, and other omics data, which increases the need for bioinformatics tools for the storage, integration, analysis, and processing of such data. The growing number of applications of NGS in precision medicine, oncology, diagnostics of rare diseases, reproductive medicine, infectious disease surveillance, and pharmacogenomics contributes to the increased need for bioinformatics solutions and software. Numerous pharmaceutical and biotech companies are using NGS-powered bioinformatics solutions for biomarker discovery, target identification, patient stratification, and diagnostic development, whereas hospitals and medical centers use NGS-powered bioinformatics solutions for genome interpretation. Moreover, progress in artificial intelligence and cloud computing makes the processing of big omics data more efficient by automating variant interpretation and omics integration.

Restraint: High cost of bioinformatics infrastructure

Bioinformatics depends on sophisticated computing hardware, robust data storage infrastructure, and a platform for analyzing and processing biological data collected through genomics and sequencing approaches. The development and maintenance of bioinformatics software and databases require substantial research and development investment. In addition, the growing volume of data generated by genomics and molecular approaches increases costs for data management, cloud computing, and cybersecurity. High labor costs are another challenge for the bioinformatics industry, as it requires expertise in biology, computer science, statistics, and data analysis.

Opportunity: Expansion of clinical bioinformatics

Clinical bioinformatics is a major market opportunity in the bioinformatics industry, driven by the growing use of genomic medicine, precision medicine, and novel diagnostic techniques. Clinical bioinformatics enables the study and analysis of complex data from the genome, proteome, and clinical domains to support disease diagnosis, treatment selection, and patient management. The rising use of next-generation sequencing (NGS) for cancer and rare disease detection, as well as for infection monitoring, is driving demand for clinical bioinformatics tools and services. Moreover, the application of AI and machine learning for disease prediction and biomarker discovery will drive market opportunities going forward.

Challenge: Management of large data volumes

The handling of large amounts of data has posed a challenge in the bioinformatics industry due to the rapid increase in biological data produced by innovations in NGS, genomics, and proteomics. Biological data has made it hard to store, integrate, analyze, and interpret biological data effectively because of the advanced computational systems required. Furthermore, data storage, integration, analysis, and interpretation are made difficult due to the requirement to ensure data privacy and adherence to regulations. Another challenge in the management of biological data is related to the management of different types of biological data from different sources.

BIOINFORMATICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides bioinformatics solutions for genomic data analysis, next-generation sequencing (NGS) workflows, molecular diagnostics, and life science research. Its platforms support sequencing data interpretation, variant analysis, and clinical research applications. Faster genomic data analysis, improved accuracy in variant interpretation, streamlined NGS workflows, enhanced research productivity, and support for precision medicine development.
Offers integrated sequencing and bioinformatics platforms for analyzing large-scale genomic data. Its solutions support applications in oncology, inherited disease research, population genomics, and clinical diagnostics through advanced sequencing data analysis. Efficient management of complex genomic datasets, improved disease identification, faster biomarker discovery, enhanced clinical decision-making, and acceleration of personalized medicine.
Provides bioinformatics software and genomic analysis platforms for sample-to-insight workflows, molecular diagnostics, clinical research, and next-generation sequencing data interpretation. Simplified data analysis, improved workflow automation, reliable genomic insights, reduced analysis time, and enhanced support for molecular testing and precision healthcare.
Develops bioinformatics tools for genomics, transcriptomics, and molecular analysis, supporting applications such as microarray analysis, NGS data interpretation, and biomarker discovery in research and clinical settings. Improved data visualization and interpretation, increased research efficiency, accurate molecular profiling, faster discovery of biological insights, and optimized laboratory workflows.
Provides integrated bioinformatics solutions supporting clinical genomics, companion diagnostics, oncology research, and precision medicine. Its platforms enable genomic data analysis for targeted therapies and biomarker identification. Enhanced biomarker assessment, faster treatment decisions, improved diagnostic accuracy, optimized clinical workflows, and support for personalized medicine approaches.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The bioinformatics market ecosystem includes major players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), and F. Hoffmann-La Roche Ltd., which provide a range of bioinformatics platforms and genomic data analytics solutions. Companies such as Fios Genomics and DNASTAR are advancing bioinformatics through specialized data analysis platforms, genomic interpretation tools, and computational solutions for life science research. The FDA and other regulatory bodies, along with companies that standardize data, are essential for data security, proper analysis, clinical validity, and the regulation of bioinformatics solutions applied in health care and research. Customers of bioinformatics solutions include hospitals, diagnostic labs, pharmaceutical and biotech companies, universities, and government organizations that use these solutions for genomic analysis, precision medicine, biomarker discovery, drug discovery, diagnostics, and biological research.

bioinformatics Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

bioinformatics Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Bioinformatics Market, By Offering

Among offerings, software held the largest share of the bioinformatics market in 2025. This is mainly due to the growing deployment of bioinformatics software, genomic analysis tools, databases, and workflows by pharma & biotech organizations, universities, hospitals, and research centers. With the rise in NGS, precision medicine, and multi-omics research, there is an increased need for advanced bioinformatics products that can help manage, analyze, and interpret massive biological data sets. Additionally, ongoing innovations in technologies such as AI-powered analysis, cloud platforms, and automation have made these bioinformatics products highly useful.

Bioinformatics Market, By Function

By function, the bioinformatics market is segmented into data analysis, structural and functional analysis, multi-omics integration, clinical interpretation, data visualization and reporting, among others. In this regard, the data analysis segment represented the largest share of the global market due to the growing volume of biological data generated by next-generation sequencing (NGS) and multi-omics technologies. Bioinformatics software has gained widespread acceptance for analyzing and interpreting complex biological data sets, generating meaningful information for drug discovery, disease research, and personalized medicine. With the adoption of AI and high-performance computing techniques in bioinformatics, the data analysis process has become more efficient. Looking ahead, with growing investments from pharmaceutical companies, biotechnology companies, and health care institutions in data-driven research and clinical applications, the segment is expected to maintain its dominance during the forecast period.

Bioinformatics Market, By Use Case

On the basis of use case, the segment for drug discovery and development accounted for the maximum share in the bioinformatics market. One of the major drivers driving the dominance of the segment is the increasing usage of bioinformatics tools in pharmaceutical and biotech firms for target identification, optimization of leads, molecular modeling, and pre-clinical research. With the developments taking place in next generation sequencing, artificial intelligence, and machine learning, researchers have been able to conduct analysis of big data sets from biological sources more quickly, resulting in faster drug discovery and better selections of candidates. In addition to that, increased investments in precision medicines, biologics, and computational drug discovery are also driving the demand.

Bioinformatics Market, By Sector

By sector, the bioinformatics market can be divided into medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, and others. Medical biotechnology had the largest market share in the bioinformatics market. This is due to the high growth rate of this segment, driven by the growing applications of bioinformatics technologies in genomics, personalized medicine, molecular diagnostics, drug discovery, and biomarker discovery. Bioinformatics technology platforms are employed by pharmaceutical companies as well as biotechnology firms to analyze genomic and clinical data sets to develop treatments, carry out clinical trials, and make clinical decisions. The increasing number of chronic diseases, cancers, and rare diseases, along with the growing application of next-generation sequencing (NGS), multi-omics platforms, and companion diagnostics, has contributed to high demand for bioinformatics solutions in medical biotechnology. Advancements in artificial intelligence (AI), machine learning, cloud computing, and computational biology have helped speed up the process of biological data analysis.

Bioinformatics Market, By End User

Pharmaceutical and biotechnology companies held the largest market share segment within the bioinformatics market's end-user segments. The growing demand for rapid drug discovery and development, optimization of clinical development, new drug targets, and precision medicine strategies will drive the adoption of bioinformatics solutions by pharmaceutical and biotech companies in the coming years. These companies generate enormous amounts of genomic, proteomic, and clinical data, making it essential for them to have bioinformatics solutions that can handle such large volumes of biological data. Next-generation sequencing, AI analysis, and omics technologies make the research process faster and help in developing drugs and discovering biomarkers. Increasing research and development, an expanding pipeline of biologics, and collaboration between pharmaceutical and biotech companies and research institutions will give a boost to this segment in the global bioinformatics market.

REGION

Asia Pacific will register the highest CAGR during the forecast period (2026-2031)

The global bioinformatics market has been classified into five regional markets, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, Asia Pacific will be the fastest-growing, owing to significant investments in genomics, biotechnology, and precision medicine. Next-generation sequencing, artificial intelligence-based bioinformatics platforms, and cloud computing-based bioinformatics platforms are driving the bioinformatics market. Governments and publicly funded research institutions continue to fund genomics and life science projects to drive innovation in these areas within the region. In addition, increased research and development spending by pharmaceutical and biotech firms, along with growing partnerships among academia, healthcare organizations, and industry players, are also driving innovation within the region. Increased investment in genomics and multi-omics research, along with venture capital and strategic investments by various life sciences firms, are driving the Asia Pacific market for bioinformatics solutions.

bioinformatics Region

BIOINFORMATICS MARKET: COMPANY EVALUATION MATRIX

In the bioinformatics market matrix, Thermo Fisher Scientific (Star Player) leads with an extensive portfolio of bioinformatics solutions for NGS, genomics, transcriptomics, and multi-omics. The company provides integrated platforms, cloud-based analysis tools, and complete genomic workflows, serving pharmaceutical and biotechnology companies, clinical labs, and research organizations. With its vast international presence, installed base, and ongoing investment in genomics and precision medicine, Thermo Fisher Scientific helps its customers achieve better results in genomic data analysis and productivity, as well as in advanced translational and clinical research. SOPHiA GENETICS (Emerging Leader) has strengthened its position with its cloud-based bioinformatics platform enhanced with artificial intelligence. The SOPHiA DDM Platform supports genomic data analysis, variant interpretation, clinical decision support, and multi-omics applications in oncology, rare diseases, and hereditary conditions. Its growing network of healthcare organizations, use of AI-based analytics, and ongoing innovation in precision medicine make SOPHiA GENETICS an emerging player with significant growth potential in the field of bioinformatics.

bioinformatics Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 16.70 BN
Market Size in 2026 (Value) USD 18.63 BN
Market Forecast in 2031 (Value) USD 34.41 BN
Growth Rate 13.1%
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Offering: Software & Bioinformatics Services
  • By Function:
    • Data Analysis
    • Structural & Functional Analysis
    • Multi-Omics Integration
    • Clinical Interpretation
    • Data Visualization & Reporting
    • Others
  • By Use Case:
    • Drug Discovery & Development
    • Precision Medicine
    • Clinical Diagnostics
    • Biomarker Discovery
    • Research & Academic Applications
    • Other Use Cases
  • By Sector:
    • Medical Biotechnology
    • Animal Biotechnology
    • Plant Biotechnology
    • Environmental Biotechnology
    • Forensic Biotechnology
    • Others
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • Hospitals & Clinical Diagnostic Laboratories
    • Contract Research Organizations (CROs) & Contract Development & Manufacturing Organizations (CDMOs)
    • Government & Public Health Organizations
    • Others
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: BIOINFORMATICS MARKET REPORT CONTENT GUIDE

bioinformatics Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Detailed Insights on Bioinformatics Products Segmented analysis of niche point solutions, knowledge management tools & end-to-end solutions, including technology trends, adoption patterns, and market sizing Facilitated targeted investment decisions across high-growth bioinformatics product and platform segments
Competitive Landscape Enhancement Additional profiling of 15–20 regional bioinformatics vendors and emerging startups Improved competitive benchmarking and partnership strategy development
Regional Market Breakout Country-level data for the US, Canada, Germany, UK, China, India, and Japan with growth drivers Supported market-entry prioritization based on market opportunity, funding landscape, and regulatory environment
End-User Workload & Adoption Insights Detailed analysis of adoption trends for pharmaceutical & biotechnology companies, hospitals & clinical diagnostic laboratories, academic & research institutes, contract research organizations & contract development & manufacturing organizations, government & public health organizations Strengthened go-to-market strategy through a deeper understanding of customer adoption patterns, unmet needs, and purchasing behavior
Bioinformatics Workflow Assessment Comprehensive analysis of genomic data processing, NGS analysis, multi-omics integration, AI-driven variant interpretation, cloud-based data management, and clinical bioinformatics workflows Enabled identification of workflow optimization opportunities, improved operational efficiency, and accelerated genomic data analysis

RECENT DEVELOPMENTS

  • May 2026 : QIAGEN enhanced its bioinformatics portfolio by integrating NVIDIA-accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights, improving AI-enabled analysis of biological data and accelerating drug discovery workflows through advanced computational capabilities.
  • March 2026 : BGI Genomics unveiled SIROmics, an AI-enabled bioinformatics solution designed to support high-throughput genetic testing by combining laboratory automation with advanced data analysis and reporting, improving workflow efficiency and accelerating genomic insights.
  • January 2026 : Illumina launched Illumina Connected Multiomics, a cloud-based research platform designed to analyze and visualize large-scale multiomic and multimodal biological data, enabling researchers to generate deeper insights through scalable and integrated data analysis.
  • November 2025 : QIAGEN announced a definitive agreement to acquire Parse Biosciences, a leading provider of scalable, instrument-free single-cell sequencing solutions. The acquisition strengthens QIAGEN's Sample Technologies portfolio and expands its presence in the rapidly growing single-cell sequencing market. It also enhances the capabilities of QIAGEN Digital Insights (QDI), enabling researchers to generate, analyze, and interpret AI-driven single-cell data more efficiently and at scale, supporting end-to-end workflows from sample preparation to actionable biological insights.
  • April 2023 : Agilent Technologies partnered with Theragen Bio under a Memorandum of Understanding (MoU) to advance precision oncology by enhancing bioinformatics solutions. The collaboration brings together Agilent's expertise in cancer genomic profiling and Theragen Bio's software capabilities to strengthen local genomic analysis and support faster, more informed treatment decisions.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
37
2
EXECUTIVE SUMMARY
 
 
 
 
 
43
3
PREMIUM INSIGHTS
 
 
 
 
 
49
4
MARKET OVERVIEW
Bioinformatics market poised for growth with AI, NGS adoption, and emerging market opportunities.
 
 
 
 
 
51
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
 
 
4.2.1.2
GROWING DEMAND FOR PERSONALIZED MEDICINE
 
 
 
 
 
 
4.2.1.3
INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY R&D EXPENDITURE
 
 
 
 
 
 
4.2.1.4
INCREASING PUBLIC AND PRIVATE-SECTOR FUNDING FOR BIOINFORMATICS
 
 
 
 
 
 
4.2.1.5
INCREASING ADOPTION OF AI AND MACHINE LEARNING IN LIFE SCIENCES
 
 
 
 
 
 
4.2.1.6
DECREASING COST OF GENOME SEQUENCING
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH COST OF BIOINFORMATICS INFRASTRUCTURE
 
 
 
 
 
 
4.2.2.2
DATA PRIVACY, SECURITY, AND REGULATORY COMPLIANCE CONCERNS
 
 
 
 
 
 
4.2.2.3
SHORTAGE OF SKILLED BIOINFORMATICS PROFESSIONALS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
LUCRATIVE OPPORTUNITIES IN EMERGING MARKETS
 
 
 
 
 
 
4.2.3.2
EXPANSION OF CLINICAL BIOINFORMATICS
 
 
 
 
 
 
4.2.3.3
ADOPTION OF CLOUD AND FEDERATED BIOINFORMATICS PLATFORMS
 
 
 
 
 
 
4.2.3.4
GROWTH OF BIOINFORMATICS OUTSOURCING SERVICES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
MANAGEMENT OF LARGE DATA VOLUMES
 
 
 
 
 
 
4.2.4.2
LACK OF INTEROPERABILITY AND MULTIPLATFORM CAPABILITIES
 
 
 
 
 
 
4.2.4.3
GROWING COMPETITION FROM IN-HOUSE DEVELOPMENT AND PUBLICLY AVAILABLE TOOLS
 
 
 
 
 
 
4.2.4.4
INTEGRATION OF MULTIOMICS DATASETS
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate competitive pressures and leverage tech advancements to excel in the evolving bioinformatics market.
 
 
 
 
 
68
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
 
5.3.1
RESEARCH & PRODUCT DEVELOPMENT
 
 
 
 
 
 
5.3.2
TECHNOLOGY INFRASTRUCTURE
 
 
 
 
 
 
5.3.3
PLATFORM DEVELOPMENT
 
 
 
 
 
 
5.3.4
DISTRIBUTION
 
 
 
 
 
 
5.3.5
MARKETING & SALES
 
 
 
 
 
 
5.3.6
POST-SALE SERVICES
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
INDICATIVE PRICING FOR BIOINFORMATICS MARKET, BY OFFERING (2025)
 
 
 
 
 
 
5.5.2
INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY REGION (2025)
 
 
 
 
 
5.6
KEY CONFERENCES AND EVENTS, 2026–2027
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.10
IMPACT OF 2025 US TARIFF –BIOINFORMATICS MARKET
 
 
 
 
 
 
 
 
5.10.1
INTRODUCTION
 
 
 
 
 
 
5.10.2
KEY TARIFF RATES
 
 
 
 
 
 
5.10.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.10.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.10.4.1
US
 
 
 
 
 
 
5.10.4.2
EUROPE
 
 
 
 
 
 
5.10.4.3
ASIA PACIFIC
 
 
 
 
 
5.10.5
IMPACT ON END USERS
 
 
 
 
 
 
 
5.10.5.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.10.5.2
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
5.10.5.3
HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
5.10.5.4
CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
 
 
 
 
 
 
5.10.5.5
GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize bioinformatics with next-gen sequencing, precision medicine, and patent breakthroughs.
 
 
 
 
 
87
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
NEXT-GENERATION SEQUENCING TECHNOLOGIES
 
 
 
 
 
 
6.1.2
ARTIFICIAL INTELLIGENCE & MACHINE LEARNING
 
 
 
 
 
 
6.1.3
MULTIOMICS ANALYSIS PLATFORMS
 
 
 
 
 
 
6.1.4
VARIANT INTERPRETATION & CLINICAL DECISION SUPPORT
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
GENERATIVE AI FOR BIOINFORMATICS
 
 
 
 
 
 
6.2.2
AI-BASED DRUG DISCOVERY PLATFORMS
 
 
 
 
 
 
6.2.3
LARGE LANGUAGE MODELS FOR LIFE SCIENCES
 
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
HIGH-PERFORMANCE COMPUTING
 
 
 
 
 
 
6.3.2
BIG DATA ANALYTICS
 
 
 
 
 
 
6.3.3
BLOCKCHAIN TECHNOLOGY
 
 
 
 
 
 
6.3.4
ROBOTICS & LABORATORY AUTOMATION
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
PATENT PUBLICATION TRENDS FOR BIOINFORMATICS MARKET
 
 
 
 
 
 
6.5.2
BIOINFORMATICS PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
 
6.6.1
AI-DRIVEN GENOMIC INTERPRETATION & CLINICAL DECISION SUPPORT
 
 
 
 
 
 
6.6.2
PRECISION MEDICINE & MULTIOMICS INTEGRATION
 
 
 
 
 
 
6.6.3
INTEGRATED BIOINFORMATICS FOR DRUG DISCOVERY & CLINICAL RESEARCH
 
 
 
 
 
6.7
IMPACT OF GEN AI IN BIOINFORMATICS MARKET
 
 
 
 
 
 
 
 
6.7.1
INTRODUCTION
 
 
 
 
 
 
6.7.2
MARKET POTENTIAL OF AI/GEN AI IN BIOINFORMATICS MARKET
 
 
 
 
 
 
6.7.3
CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
 
 
 
 
 
 
 
 
AI-POWERED GENOMICS FOR PRECISION MEDICINE AT ILLUMINA AND
 
 
 
 
 
6.7.4
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 
 
 
 
 
 
 
6.7.4.1
AI IN BIOINFORMATICS SOFTWARE MARKET
 
 
 
 
 
 
6.7.4.2
NEXT-GENERATION SEQUENCING MARKET
 
 
 
 
 
 
6.7.4.3
DRUG DISCOVERY MARKET
 
 
 
 
 
6.7.5
USERS READINESS AND IMPACT ASSESSMENT
 
 
 
 
 
 
 
6.7.5.1
USER READINESS
 
 
 
 
 
 
 
 
6.7.5.1.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
6.7.5.1.2
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
6.7.5.1.3
HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
6.7.5.1.4
CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
 
 
 
 
6.7.5.2
IMPACT ASSESSMENT
 
 
 
 
 
 
 
 
6.7.5.2.1
USER A: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
6.7.5.2.2
USER B: ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
6.7.5.2.3
USER C: HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
6.7.5.2.4
USER D: CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
 
7
REGULATORY LANDSCAPE
Navigate global compliance with detailed insights into regional regulatory bodies and frameworks.
 
 
 
 
 
104
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
REGULATORY FRAMEWORK
 
 
 
 
 
 
 
7.1.2.1
NORTH AMERICA
 
 
 
 
 
 
7.1.2.2
EUROPE
 
 
 
 
 
 
7.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.2.4
LATIN AMERICA
 
 
 
 
 
 
7.1.2.5
MIDDLE EAST & AFRICA
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand buyer dynamics: unmet needs and criteria shape stakeholder influence in decision-making.
 
 
 
 
 
113
 
8.1
INTRODUCTION
 
 
 
 
 
 
8.2
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.3
STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.3.2
BUYING CRITERIA
 
 
 
 
 
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.5
UNMET NEEDS FROM VARIOUS END USERS
 
 
 
 
 
 
 
8.5.1
UNMET NEEDS
 
 
 
 
 
 
8.5.2
END USER EXPECTATIONS
 
 
 
 
 
8.6
MARKET PROFITABILITY
 
 
 
 
 
9
BIOINFORMATICS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 43 Data Tables
 
 
 
 
 
121
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
SOFTWARE
 
 
 
 
 
 
 
9.2.1
NICHE POINT SOLUTIONS
 
 
 
 
 
 
 
9.2.1.1
INCREASING ADOPTION OF NGS AND MULTIOMICS TECHNOLOGIES TO BOOST GROWTH
 
 
 
 
 
9.2.2
KNOWLEDGE MANAGEMENT TOOLS
 
 
 
 
 
 
 
9.2.2.1
RISING DEMAND FOR GENOMIC VARIANT INTERPRETATION DATABASES
 
 
 
 
 
 
9.2.2.2
GENERALIZED KNOWLEDGE MANAGEMENT TOOLS
 
 
 
 
 
 
 
 
9.2.2.2.1
DEVELOPMENT OF NOVEL GENERALIZED KNOWLEDGE MANAGEMENT TOOLS TO DRIVE GROWTH
 
 
 
 
9.2.2.3
SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS
 
 
 
 
 
 
 
 
9.2.2.3.1
DATA SECURITY AND HIGHLY RELIABLE INFORMATION STORAGE SYSTEMS TO SUPPORT GROWTH
 
 
 
9.2.3
END-TO-END SOLUTIONS
 
 
 
 
 
 
 
9.2.3.1
INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) TO DRIVE GROWTH
 
 
 
 
 
 
9.2.3.2
GENOMIC SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.2.1
EXPANSION OF PRECISION MEDICINE AND GENOMIC DIAGNOSTICS – SEGMENT DRIVER
 
 
 
 
9.2.3.3
MULTIOMICS SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.3.1
INCREASING INTEGRATION OF GENOMICS, TRANSCRIPTOMICS, PROTEOMICS, AND METABOLOMICS DATASET TO DRIVE MARKET
 
 
 
 
9.2.3.4
CHEMOINFORMATICS SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.4.1
INCREASING INVESTMENT IN R&D TO BOOST SEGMENT
 
 
 
 
9.2.3.5
PROTEOMICS SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.5.1
GROWING FOCUS ON PROTEIN BIOMARKER DISCOVERY FUELS ADOPTION
 
 
 
 
9.2.3.6
TRANSCRIPTOMICS SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.6.1
RISING DEMAND FOR GENE EXPRESSION ANALYSIS ACCELERATES ADOPTION
 
 
 
 
9.2.3.7
METABOLOMICS SOLUTIONS
 
 
 
 
 
 
 
 
9.2.3.7.1
ADOPTION OF LC-MS AND GC-MS TECHNOLOGIES ACCELERATES SEGMENT GROWTH
 
 
 
 
9.2.3.8
OTHER END-TO-END SOLUTIONS
 
 
 
 
9.3
SERVICES
 
 
 
 
 
 
 
9.3.1
SEQUENCING & DATA GENERATION
 
 
 
 
 
 
 
9.3.1.1
INCREASING ADOPTION OF NGS DRIVES DEMAND
 
 
 
 
 
9.3.2
DATA ANALYSIS & INTERPRETATION
 
 
 
 
 
 
 
9.3.2.1
GROWING COMPLEXITY OF MULTIOMICS DATA DRIVES DEMAND
 
 
 
 
 
9.3.3
DRUG DISCOVERY & TARGET IDENTIFICATION
 
 
 
 
 
 
 
9.3.3.1
INCREASING ADOPTION OF PRECISION MEDICINE FUELS DEMAND
 
 
 
 
 
9.3.4
DATABASE & DATA MANAGEMENT
 
 
 
 
 
 
 
9.3.4.1
EXPONENTIAL GROWTH OF BIOLOGICAL DATA DRIVES SEGMENT
 
 
 
 
 
9.3.5
CLOUD & MANAGED BIOINFORMATICS
 
 
 
 
 
 
 
9.3.5.1
INCREASING ADOPTION OF CLOUD COMPUTING ACCELERATES SEGMENT GROWTH
 
 
 
 
 
9.3.6
CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT
 
 
 
 
 
 
 
9.3.6.1
INCREASING DEMAND FOR CUSTOMIZED BIOINFORMATICS WORKFLOWS BOOSTS SEGMENT
 
 
 
 
 
9.3.7
OTHER SERVICES
 
 
 
 
10
BIOINFORMATICS MARKET, BY FUNCTION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 12 Data Tables
 
 
 
 
 
150
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
DATA ANALYSIS
 
 
 
 
 
 
 
10.2.1
SEQUENCE ANALYSIS
 
 
 
 
 
 
 
10.2.1.1
GROWING VOLUME OF SEQUENCING DATA DRIVES DEMAND
 
 
 
 
 
10.2.2
VARIANT ANALYSIS
 
 
 
 
 
 
 
10.2.2.1
INCREASING ADOPTION OF PRECISION MEDICINE TO BOOST SEGMENT
 
 
 
 
 
10.2.3
GENE EXPRESSION ANALYSIS
 
 
 
 
 
 
 
10.2.3.1
EXPANDING TRANSCRIPTOMICS RESEARCH DRIVES SEGMENT GROWTH
 
 
 
 
 
10.2.4
OTHER DATA ANALYSIS FUNCTIONS
 
 
 
 
 
10.3
STRUCTURAL & FUNCTIONAL ANALYSIS
 
 
 
 
 
 
 
10.3.1
GROWING ADOPTION OF STRUCTURE-BASED DRUG DISCOVERY AND PROTEIN MODELING TO BOOST GROWTH
 
 
 
 
 
10.4
MULTIOMICS INTEGRATION
 
 
 
 
 
 
 
10.4.1
INCREASING INTEGRATION OF MULTIOMICS DATA DRIVES DEMAND FOR ADVANCED BIOINFORMATICS PLATFORMS
 
 
 
 
 
10.5
CLINICAL INTERPRETATION
 
 
 
 
 
 
 
10.5.1
GROWING ADOPTION OF PRECISION MEDICINE AND CLINICAL GENOMICS IS PROPELS GROWTH
 
 
 
 
 
10.6
DATA VISUALIZATION & REPORTING
 
 
 
 
 
 
 
10.6.1
INCREASING ADOPTION OF AI-DRIVEN DRUG DISCOVERY AND COMPUTATIONAL CHEMISTRY – KEY SEGMENT DRIVER
 
 
 
 
 
10.7
OTHER FUNCTIONS
 
 
 
 
 
11
BIOINFORMATICS MARKET, BY USE CASE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
161
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
DRUG DISCOVERY & DEVELOPMENT
 
 
 
 
 
 
 
11.2.1
GROWING PHARMACEUTICAL R&D INVESTMENTS DRIVE GROWTH
 
 
 
 
 
11.3
PRECISION MEDICINE
 
 
 
 
 
 
 
11.3.1
INCREASING DEMAND FOR PERSONALIZED TREATMENT STRATEGIES TO BOOST SEGMENT
 
 
 
 
 
11.4
CLINICAL DIAGNOSTICS
 
 
 
 
 
 
 
11.4.1
GROWING ADOPTION OF GENOMIC TESTING – KEY DRIVER
 
 
 
 
 
11.5
BIOMARKER DISCOVERY
 
 
 
 
 
 
 
11.5.1
GROWING FOCUS ON PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO BOOST SEGMENT
 
 
 
 
 
11.6
RESEARCH & ACADEMIC APPLICATIONS
 
 
 
 
 
 
 
11.6.1
INCREASING INVESTMENTS IN LIFE SCIENCE RESEARCH PROPEL SEGMENT GROWTH
 
 
 
 
 
11.7
OTHER USE CASES
 
 
 
 
 
12
BIOINFORMATICS MARKET, BY SECTOR
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
169
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
MEDICAL BIOTECHNOLOGY
 
 
 
 
 
 
 
12.2.1
EXPANSION OF GENOMIC DIAGNOSTICS, MOLECULAR TESTING, AND PERSONALIZED HEALTHCARE TO DRIVE SEGMENT
 
 
 
 
 
12.3
ANIMAL BIOTECHNOLOGY
 
 
 
 
 
 
 
12.3.1
INCREASING ADOPTION OF PRECISION LIVESTOCK FARMING AND VETERINARY GENOMICS TO PROPEL GROWTH
 
 
 
 
 
12.4
PLANT BIOTECHNOLOGY
 
 
 
 
 
 
 
12.4.1
GROWING DEMAND FOR CLIMATE-RESILIENT AND HIGH-YIELD CROPS TO BOOST SEGMENT
 
 
 
 
 
12.5
ENVIRONMENTAL BIOTECHNOLOGY
 
 
 
 
 
 
 
12.5.1
INCREASING ADOPTION OF ENVIRONMENTAL DNA (EDNA) AND METAGENOMICS BOOSTS GROWTH
 
 
 
 
 
12.6
FORENSIC BIOTECHNOLOGY
 
 
 
 
 
 
 
12.6.1
INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING AND FORENSIC GENOMICS TO DRIVE SEGMENT
 
 
 
 
 
12.7
OTHER SECTORS
 
 
 
 
 
13
BIOINFORMATICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
177
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
 
INCREASING PHARMACEUTICAL R&D INVESTMENTS
 
 
 
 
 
13.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
 
GROWING GOVERNMENT FUNDING FOR BIOMEDICAL
 
 
 
 
 
13.4
HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
 
13.4.1
INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
 
 
 
 
 
13.5
CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
 
 
 
 
 
 
 
13.5.1
INCREASING OUTSOURCING OF DRUG DEVELOPMENT AND GROWING DEMAND FOR SPECIALIZED COMPUTATIONAL EXPERTISE
 
 
 
 
 
13.6
GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS
 
 
 
 
 
 
 
13.6.1
INCREASING INVESTMENTS IN GENOMIC SURVEILLANCE AND PUBLIC HEALTH INFORMATICS
 
 
 
 
 
13.7
OTHER END USERS
 
 
 
 
 
14
BIOINFORMATICS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 17 Countries | 287 Data Tables.
 
 
 
 
 
186
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
14.2.2
US
 
 
 
 
 
 
 
14.2.2.1
STRONG GOVERNMENT SUPPORT AND RAPID ADVANCES IN GENOMICS AND AI DRIVE MARKET
 
 
 
 
 
14.2.3
CANADA
 
 
 
 
 
 
 
14.2.3.1
INCREASING GOVERNMENT INVESTMENTS IN GENOMICS AND NATIONAL BIOINFORMATICS INFRASTRUCTURE
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
14.3.2
GERMANY
 
 
 
 
 
 
 
14.3.2.1
STRONG GOVERNMENT INVESTMENTS IN PRECISION MEDICINE AND EXPANDING AI-ENABLED BIOINFORMATICS RESEARCH
 
 
 
 
 
14.3.3
UK
 
 
 
 
 
 
 
14.3.3.1
STRATEGIC INITIATIVES AND FUNDING FOR GENOMICS RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.4
FRANCE
 
 
 
 
 
 
 
14.3.4.1
MARKET DRIVEN BY NATIONAL GENOMICS PROGRAMS AND AI-ENABLED BIOMEDICAL RESEARCH
 
 
 
 
 
14.3.5
ITALY
 
 
 
 
 
 
 
14.3.5.1
FAVORABLE FUNDING SCENARIO TO DRIVE ADOPTION OF ADVANCED SEQUENCING TECHNOLOGY
 
 
 
 
 
14.3.6
SPAIN
 
 
 
 
 
 
 
14.3.6.1
GROWING FOCUS ON ADVANCEMENTS IN PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.7
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
14.4.2
CHINA
 
 
 
 
 
 
 
14.4.2.1
EXPANSION OF NATIONAL GENOMIC DATA INFRASTRUCTURE DRIVES MARKET
 
 
 
 
 
14.4.3
JAPAN
 
 
 
 
 
 
 
14.4.3.1
RISING NUMBER OF COLLABORATIONS IN BIOINFORMATICS TO DRIVE MARKET
 
 
 
 
 
14.4.4
INDIA
 
 
 
 
 
 
 
14.4.4.1
GOVERNMENT AND PRIVATE INITIATIVES FOR GENOMICS PROJECTS TO PROPEL MARKET
 
 
 
 
 
14.4.5
AUSTRALIA
 
 
 
 
 
 
 
14.4.5.1
INCREASED GENETIC RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.4.6
SOUTH KOREA
 
 
 
 
 
 
 
14.4.6.1
NATIONAL BIOMEDICAL DATA INTEGRATION AND AI-DRIVEN PRECISION MEDICINE ACCELERATE MARKET
 
 
 
 
 
14.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
 
 
14.5.2.1
INCREASED GOVERNMENT INVESTMENTS IN GENOMICS ADVANCEMENTS TO DRIVE MARKET
 
 
 
 
 
14.5.3
MEXICO
 
 
 
 
 
 
 
14.5.3.1
RISING DEMAND FOR CHRONIC DISEASE TREATMENT TO SUPPORT GROWTH
 
 
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
14.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
14.6.2.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
14.6.2.1.1
GROWING HEALTHCARE EXPENDITURE TO BOOST MARKET GROWTH
 
 
 
 
14.6.2.2
UAE
 
 
 
 
 
 
 
 
14.6.2.2.1
COLLABORATIONS TO ADVANCE GENOME SEQUENCING AND MARKET GROWTH
 
 
 
 
14.6.2.3
REST OF GCC
 
 
 
 
 
14.6.3
SOUTH AFRICA
 
 
 
 
 
 
 
14.6.3.1
GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET
 
 
 
 
 
14.6.4
REST OF MIDDLE EAST & AFRICA
 
 
 
 
15
COMPETITIVE LANDSCAPE
Uncover strategic dominance and emerging threats shaping the competitive landscape through 2025.
 
 
 
 
 
345
 
15.1
OVERVIEW
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026
 
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2021–2025
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
15.5
BRAND COMPARISON
 
 
 
 
 
 
 
15.6
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
15.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
15.7.1
STARS
 
 
 
 
 
 
15.7.2
EMERGING LEADERS
 
 
 
 
 
 
15.7.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.7.4
PARTICIPANTS
 
 
 
 
 
 
15.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
15.7.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.7.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.7.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
15.7.5.4
FUNCTION FOOTPRINT
 
 
 
 
 
 
15.7.5.5
USE CASE FOOTPRINT
 
 
 
 
 
 
15.7.5.6
END USER FOOTPRINT
 
 
 
 
15.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
15.8.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.8.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.8.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.8.4
STARTING BLOCKS
 
 
 
 
 
 
15.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
15.8.5.1
LIST OF STARTUPS/SMES
 
 
 
 
 
 
15.8.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT LAUNCHES & ENHANCEMENTS
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
 
 
15.9.4
OTHER DEVELOPMENTS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
371
 
16.1
KEY COMPANIES
 
 
 
 
 
 
 
16.1.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT LAUNCHES
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
 
 
16.1.1.3.3
EXPANSIONS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
16.1.2
ILLUMINA, INC.
 
 
 
 
 
 
16.1.3
QIAGEN N.V.
 
 
 
 
 
 
16.1.4
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
16.1.5
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
 
16.1.6
REVVITY, INC.
 
 
 
 
 
 
16.1.7
EUROFINS SCIENTIFIC
 
 
 
 
 
 
16.1.8
BGI GENOMICS
 
 
 
 
 
 
16.1.9
WATERS CORPORATION
 
 
 
 
 
 
16.1.10
DNANEXUS, INC.
 
 
 
 
 
 
16.1.11
OXFORD NANOPORE TECHNOLOGIES PLC
 
 
 
 
 
 
16.1.12
10X GENOMICS
 
 
 
 
 
 
16.1.13
PACBIO
 
 
 
 
 
 
16.1.14
SIEMENS AG
 
 
 
 
 
 
16.1.15
SOPHIA GENETICS
 
 
 
 
 
 
16.1.16
EXCELRA
 
 
 
 
 
 
16.1.17
GENEWIZ (AZENTA LIFE SCIENCES)
 
 
 
 
 
 
16.1.18
ONTOFORCE
 
 
 
 
 
 
16.1.19
VELSERA INC.
 
 
 
 
 
 
16.1.20
SEQERA
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
DNASTAR
 
 
 
 
 
 
16.2.2
FIOS GENOMICS
 
 
 
 
 
 
16.2.3
DEEP GENOMICS
 
 
 
 
 
 
16.2.4
PSOMAGEN
 
 
 
 
 
 
16.2.5
SOURCE BIOSCIENCE
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
460
 
17.1
RESEARCH APPROACH
 
 
 
 
 
 
 
17.1.1
SECONDARY RESEARCH
 
 
 
 
 
 
 
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
17.1.2
PRIMARY RESEARCH
 
 
 
 
 
 
 
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
17.1.2.2
BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
17.1.2.3
INSIGHTS FROM PRIMARY EXPERTS
 
 
 
 
17.2
RESEARCH METHODOLOGY DESIGN
 
 
 
 
 
 
17.3
MARKET SIZE ESTIMATION
 
 
 
 
 
 
17.4
MARKET BREAKDOWN DATA TRIANGULATION
 
 
 
 
 
 
17.5
MARKET SHARE ESTIMATION
 
 
 
 
 
 
17.6
STUDY ASSUMPTIONS
 
 
 
 
 
 
17.7
RESEARCH LIMITATIONS
 
 
 
 
 
 
 
17.7.1
METHODOLOGY-RELATED LIMITATIONS
 
 
 
 
 
 
17.7.2
SCOPE-RELATED LIMITATIONS
 
 
 
 
 
17.8
RISK ASSESSMENT
 
 
 
 
 
18
APPENDIX
 
 
 
 
 
477
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
EXCHANGE RATES FOR CONVERSION TO USD
 
 
 
 
 
 
TABLE 2
ASIA PACIFIC: R&D INVESTMENT BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
TABLE 3
PUBLIC AND PRIVATE-SECTOR FUNDING FOR BIOINFORMATICS AND RELATED FIELDS
 
 
 
 
 
 
TABLE 4
BIOINFORMATICS MARKET: PORTER’S FIVE FORCES
 
 
 
 
 
 
TABLE 5
BIOINFORMATICS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY OFFERING (2025)
 
 
 
 
 
 
TABLE 7
INDICATIVE PRICING OF SOFTWARE (NICHE POINT SOLUTIONS), BY REGION (2025)
 
 
 
 
 
 
TABLE 8
BIOINFORMATICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 9
CASE 1: FASTER WORKFLOWS, COST-EFFICIENCY, AND SIMPLIFIED INFRASTRUCTURE
 
 
 
 
 
 
TABLE 10
CASE STUDY 2: COMPREHENSIVE CLINICAL EXOME ANALYSIS TO SUPPORT DIVERSE APPLICATIONS AT HENRY FORD HEALTH
 
 
 
 
 
 
TABLE 11
CASE STUDY 2: CHAMPIONS ONCOLOGY SCALES MULTIOMICS ANALYSIS WITH SEQERA TO ACCELERATE CANCER THERAPY DEVELOPMENT
 
 
 
 
 
 
TABLE 12
US ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 13
COUNTRY
 
 
 
 
 
 
TABLE 14
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR BIOINFORMATICS MARKET
 
 
 
 
 
 
TABLE 15
BIOINFORMATICS MARKET: KEY PATENTS/PATENT APPLICATIONS
 
 
 
 
 
 
TABLE 16
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 17
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
REGULATORY SCENARIO IN NORTH AMERICA
 
 
 
 
 
 
TABLE 22
REGULATORY SCENARIO IN EUROPE
 
 
 
 
 
 
TABLE 23
REGULATORY SCENARIO IN ASIA PACIFIC
 
 
 
 
 
 
TABLE 24
REGULATORY SCENARIO IN LATIN AMERICA
 
 
 
 
 
 
TABLE 25
REGULATORY SCENARIO IN MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 26
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
 
 
 
 
 
 
TABLE 27
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
TABLE 28
UNMET NEEDS IN BIOINFORMATICS MARKET
 
 
 
 
 
 
TABLE 29
END USER EXPECTATIONS IN BIOINFORMATICS MARKET
 
 
 
 
 
 
TABLE 30
BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
BIOINFORMATICS MARKET FOR SOFTWARE, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 33
NICHE POINT SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 34
BIOINFORMATICS MARKET FOR NICHE POINT SOLUTIONS, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 35
BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
GENERALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 38
BIOINFORMATICS MARKET FOR GENERALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 40
BIOINFORMATICS MARKET FOR SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
GENOMIC SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 44
BIOINFORMATICS MARKET FOR GENOMIC SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
MULTIOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 46
BIOINFORMATICS MARKET FOR MULTIOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
CHEMOINFORMATICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 48
BIOINFORMATICS MARKET FOR CHEMOINFORMATICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
PROTEOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 50
BIOINFORMATICS MARKET FOR PROTEOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
TRANSCRIPTOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 52
BIOINFORMATICS MARKET FOR TRANSCRIPTOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
METABOLOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 54
BIOINFORMATICS MARKET FOR METABOLOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
OTHER END-TO-END SOLUTIONS OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 56
BIOINFORMATICS MARKET FOR OTHER END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
BIOINFORMATICS MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
SEQUENCING & DATA GENERATION SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 60
BIOINFORMATICS MARKET FOR SEQUENCING & DATA GENERATION SERVICES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
DATA ANALYSIS & INTERPRETATION SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 62
BIOINFORMATICS MARKET FOR DATA ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
DRUG DISCOVERY & TARGET IDENTIFICATION OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 64
BIOINFORMATICS MARKET FOR DRUG DISCOVERY & TARGET IDENTIFICATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
DATABASE & DATA MANAGEMENT SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 66
BIOINFORMATICS MARKET FOR DATABASE & DATA MANAGEMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
CLOUD & MANAGED BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 68
BIOINFORMATICS MARKET FOR CLOUD & MANAGED BIOINFORMATICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 70
BIOINFORMATICS MARKET FOR CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
OTHER BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS
 
 
 
 
 
 
TABLE 72
BIOINFORMATICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
BIOINFORMATICS MARKET FOR SEQUENCE ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
BIOINFORMATICS MARKET FOR VARIANT ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
BIOINFORMATICS MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
BIOINFORMATICS MARKET FOR OTHER DATA ANALYSIS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
BIOINFORMATICS MARKET FOR STRUCTURAL & FUNCTIONAL ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
BIOINFORMATICS MARKET FOR MULTIOMICS INTEGRATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
BIOINFORMATICS MARKET FOR CLINICAL INTERPRETATION, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
BIOINFORMATICS MARKET FOR DATA VISUALIZATION & REPORTING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
BIOINFORMATICS MARKET FOR OTHER FUNCTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
BIOINFORMATICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
BIOINFORMATICS MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
BIOINFORMATICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
BIOINFORMATICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
BIOINFORMATICS MARKET FOR RESEARCH & ACADEMIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
BIOINFORMATICS MARKET FOR OTHER USE CASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
BIOINFORMATICS MARKET FOR MEDICAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
BIOINFORMATICS MARKET FOR ANIMAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
BIOINFORMATICS MARKET FOR PLANT BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
BIOINFORMATICS MARKET FOR ENVIRONMENTAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
BIOINFORMATICS MARKET FOR FORENSIC BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
BIOINFORMATICS MARKET FOR OTHER SECTORS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
BIOINFORMATICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
BIOINFORMATICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
BIOINFORMATICS MARKET FOR HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
BIOINFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
BIOINFORMATICS MARKET FOR GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
BIOINFORMATICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
BIOINFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
NORTH AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
NORTH AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
NORTH AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
NORTH AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
NORTH AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
NORTH AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
NORTH AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
NORTH AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
NORTH AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
NORTH AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
NORTH AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
US: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
US: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
US: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
US: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
US: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
US: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
US: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
US: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
US: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
US: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
CANADA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
CANADA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
CANADA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
CANADA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
CANADA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
CANADA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
CANADA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
CANADA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
CANADA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
CANADA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
EUROPE: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
GERMANY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
GERMANY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
GERMANY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
GERMANY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
GERMANY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
GERMANY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
GERMANY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
GERMANY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
GERMANY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
GERMANY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
UK: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
UK: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
UK: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
UK: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
UK: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
UK: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
UK: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
UK: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
UK: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
UK: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
FRANCE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
FRANCE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
FRANCE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
FRANCE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
FRANCE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
FRANCE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
FRANCE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
FRANCE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
FRANCE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
FRANCE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
ITALY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
ITALY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
ITALY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
ITALY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
ITALY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
ITALY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
ITALY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
ITALY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
ITALY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
ITALY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
SPAIN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
SPAIN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
SPAIN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
SPAIN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
SPAIN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
SPAIN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
SPAIN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
SPAIN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
SPAIN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
SPAIN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
REST OF EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
REST OF EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
REST OF EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
REST OF EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
REST OF EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
REST OF EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
REST OF EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
REST OF EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
REST OF EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
REST OF EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
ASIA PACIFIC: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
CHINA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
CHINA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
CHINA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
CHINA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
CHINA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
CHINA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
CHINA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
CHINA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
CHINA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
CHINA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
JAPAN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
JAPAN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
JAPAN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
JAPAN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
JAPAN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
JAPAN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
JAPAN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
JAPAN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
JAPAN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
JAPAN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
INDIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
INDIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
INDIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
INDIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
INDIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
INDIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
INDIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
INDIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
INDIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
INDIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
AUSTRALIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
AUSTRALIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
AUSTRALIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
AUSTRALIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
AUSTRALIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
AUSTRALIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
AUSTRALIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
AUSTRALIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
AUSTRALIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
AUSTRALIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
SOUTH KOREA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
SOUTH KOREA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
SOUTH KOREA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
SOUTH KOREA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
SOUTH KOREA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
SOUTH KOREA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
SOUTH KOREA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
SOUTH KOREA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
SOUTH KOREA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
SOUTH KOREA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
LATIN AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
BRAZIL: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
BRAZIL: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
BRAZIL: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
BRAZIL: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
BRAZIL: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
BRAZIL: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
BRAZIL: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
BRAZIL: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
BRAZIL: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
BRAZIL: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
MEXICO: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
MEXICO: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
MEXICO: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
MEXICO: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
MEXICO: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
MEXICO: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
MEXICO: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
MEXICO: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
MEXICO: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
MEXICO: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
GCC COUNTRIES: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
GCC COUNTRIES: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
GCC COUNTRIES: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
GCC COUNTRIES: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
GCC COUNTRIES: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
GCC COUNTRIES: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
GCC COUNTRIES: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
GCC COUNTRIES: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
GCC COUNTRIES: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
GCC COUNTRIES: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
GCC COUNTRIES: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
SAUDI ARABIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
SAUDI ARABIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
SAUDI ARABIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
SAUDI ARABIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
SAUDI ARABIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
SAUDI ARABIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
SAUDI ARABIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
SAUDI ARABIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
SAUDI ARABIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
SAUDI ARABIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
UAE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
UAE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
UAE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
UAE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
UAE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
UAE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
UAE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
UAE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
UAE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
UAE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
REST OF GCC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
REST OF GCC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
REST OF GCC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
REST OF GCC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
REST OF GCC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
REST OF GCC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
REST OF GCC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
REST OF GCC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
REST OF GCC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
REST OF GCC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
SOUTH AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
SOUTH AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
SOUTH AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
SOUTH AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
SOUTH AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
SOUTH AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
SOUTH AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
SOUTH AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
SOUTH AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
SOUTH AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026
 
 
 
 
 
 
TABLE 394
BIOINFORMATICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 395
BIOINFORMATICS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 396
BIOINFORMATICS MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 397
BIOINFORMATICS MARKET: FUNCTION FOOTPRINT
 
 
 
 
 
 
TABLE 398
BIOINFORMATICS MARKET: USE CASE FOOTPRINT
 
 
 
 
 
 
TABLE 399
BIOINFORMATICS MARKET: END USER FOOTPRINT
 
 
 
 
 
 
TABLE 400
BIOINFORMATICS MARKET: LIST OF STARTUPS/SMES
 
 
 
 
 
 
TABLE 401
BIOINFORMATICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
 
 
TABLE 402
BIOINFORMATICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2023–2026
 
 
 
 
 
 
TABLE 403
BIOINFORMATICS MARKET: DEALS, 2023–2026
 
 
 
 
 
 
TABLE 404
BIOINFORMATICS MARKET: EXPANSIONS, 2023–2026
 
 
 
 
 
 
TABLE 405
BIOINFORMATICS MARKET: OTHER DEVELOPMENTS, 2023–2026
 
 
 
 
 
 
TABLE 406
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 407
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 408
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 409
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 410
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 411
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 412
ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 413
ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 414
ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 415
ILLUMINA, INC.: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 416
QIAGEN N.V.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 417
QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 418
QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 419
QIAGEN N.V.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 420
QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 421
QIAGEN N.V.: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 422
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 423
AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 424
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023−JULY 2026
 
 
 
 
 
 
TABLE 425
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 426
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 427
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 428
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 429
F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 430
REVVITY, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 431
REVVITY, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 432
REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 433
REVVITY, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 434
REVVITY: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 435
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 436
EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 437
EUROFINS SCIENTIFIC: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 438
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 439
BGI GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 440
BGI GENOMICS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 441
BGI GENOMICS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 442
WATERS CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 443
WATERS CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 444
DNANEXUS, INC. COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 445
DNANEXUS, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 446
DNANEXUS, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 447
DNANEXUS, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 448
DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 449
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 450
OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 451
OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 452
OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023- JULY 2026
 
 
 
 
 
 
TABLE 453
10X GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 454
10X GENOMICS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 455
10X GENOMICS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 456
PACBIO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 457
PACBIO: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 458
PACBIO: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 459
PACBIO: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 460
PACBIO: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 461
SIEMENS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 462
SIEMENS AG: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 463
SIEMENS AG: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 464
SIEMENS AG: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 465
SIEMENS AG: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 466
SOPHIA GENETICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 467
SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 468
SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 469
SOPHIA GENETICS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 470
SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 471
EXCELRA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 472
EXCELRA: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 473
EXCELRA: PRODUCT ENHANCEMENT, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 474
EXCELRA: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 475
GENEWIZ (AZENTA LIFE SCIENCES): COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 476
GENEWIZ (AZENTA LIFE SCIENCES): PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 477
GENEWIZ (AZENTA LIFE SCIENCES): DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 478
GENEWIZ (AZENTA LIFE SCIENCES): OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 479
ONTOFORCE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 480
ONTOFORCE: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 481
ONTOFORCE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 482
ONTOFORCE: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 483
VELSERA INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 484
VELSERA INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 485
VELSERA INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 486
SEQERA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 487
SEQERA: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 488
SEQERA: PRODUCT LAUNCHES & ENHANCEMENT, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 489
SEQERA: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 490
SEQERA: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 491
RISK ASSESSMENT: BIOINFORMATICS MARKET
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 2
GLOBAL BIOINFORMATICS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOINFORMATICS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 4
DISRUPTIONS INFLUENCING GROWTH OF BIOINFORMATICS MARKET
 
 
 
 
 
 
FIGURE 5
HIGH-GROWTH SEGMENTS IN BIOINFORMATICS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOINFORMATICS MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 7
INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
SOFTWARE ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 9
INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
BIOINFORMATICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 11
GLOBAL CANCER INCIDENCE, 2008−2030
 
 
 
 
 
 
FIGURE 12
FDA-APPROVED PERSONALIZED MEDICINES, 2015−2024
 
 
 
 
 
 
FIGURE 13
BIOINFORMATICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 14
BIOINFORMATICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 15
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 16
REVENUE SHIFT IN BIOINFORMATICS MARKET
 
 
 
 
 
 
FIGURE 17
RECENT FUNDING OF PLAYERS IN BIOINFORMATICS MARKET
 
 
 
 
 
 
FIGURE 18
PATENT PUBLICATION TRENDS IN BIOINFORMATICS MARKET, 2015–2026
 
 
 
 
 
 
FIGURE 19
JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOINFORMATICS MARKET
 
 
 
 
 
 
FIGURE 20
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) IN BIOINFORMATICS MARKET (JANUARY 2015–JULY 2026)
 
 
 
 
 
 
FIGURE 21
MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING BIOINFORMATICS
 
 
 
 
 
 
FIGURE 22
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 
 
 
 
 
 
FIGURE 23
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 24
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 25
NORTH AMERICA: BIOINFORMATICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
ASIA PACIFIC: BIOINFORMATICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
REVENUE ANALYSIS OF TOP LISTED/PUBLIC PLAYERS, 2021–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 28
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
 
 
 
 
 
 
FIGURE 29
BRAND COMPARISON
 
 
 
 
 
 
FIGURE 30
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 31
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 32
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 33
BIOINFORMATICS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 34
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 35
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
QIAGEN N.V.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
GILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
REVVITY, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
WATERS CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
10X GENOMICS: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
PACBIO: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
SIEMENS AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
SOPHIA GENETICS: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
AZENTA INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 49
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 50
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 51
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 
 
 
 
 
 
FIGURE 52
BOTTOM-UP APPROACH
 
 
 
 
 
 
FIGURE 53
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 54
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOINFORMATICS MARKET
 
 
 
 
 
 
FIGURE 55
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 56
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

Methodology

This research study involved the extensive use of both primary and secondary sources. It analyzed various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

Secondary Research

This research study extensively used secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive, commercially focused study of the bioinformatics market, covering technical aspects and market dynamics. It also helped identify key players, market classifications, industry trends, geographic markets, and significant market developments. Additionally, a database of prominent industry leaders was compiled through secondary research.

Primary Research

In the primary research process, various supply-side and demand-side sources were interviewed to gather qualitative and quantitative information for this report. Primary supply-side sources included industry experts such as CEOs, VPs, managing directors, marketing and sales heads/directors, marketing managers, regional/area sales managers, and bioinformatics scientists. Primary demand-side sources included personnel from pharmaceutical and biotechnology companies, hospitals, diagnostic laboratories, and academic and research institutes.

A breakdown of the primary respondents is provided below:

Bioinformatics Market Size, and Share

*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the bioinformatics market was determined after data triangulation using the two approaches outlined below. After each approach was completed, the weighted average of the two approaches was calculated based on the level of assumptions used in each approach.

Bioinformatics Market : Top-Down and Bottom-Up Approach

Bioinformatics Market Top Down and Bottom Up Approach

Data Triangulation

The size of the bioinformatics market was estimated through segmental extrapolation using the bottom-up approach. The methodology is as follows:

  • Revenue information of individual companies was gathered from public sources and databases.
  • The share of leading players in the bioinformatics market was obtained from secondary sources to the extent available. In certain cases, shares of bioinformatics businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach and strength. 
  • Individual shares or revenue estimates were validated through interviews with experts.
  • The total revenue in the bioinformatics market was determined by extrapolating the market share data of major companies.

Market Definition

Bioinformatics is the application of computer technology to the management and analysis of biological data. It encompasses the storage, analysis, and dissemination of biological data. Bioinformatics uses computer programs for a variety of applications, including determining gene and protein functions, establishing evolutionary relationships, and predicting the three-dimensional shapes of proteins.

Key Stakeholders

  • Bioinformatics software and service providers
  • Academic & research institutes
  • Clinical & diagnostic laboratories
  • Hospitals & healthcare providers
  • Contract research organizations (CROs)
  • Distributors and suppliers of bioinformatics software and services
  • Pharmaceutical & biotechnology companies
  • Market research and consulting firms
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the bioinformatics market based on offering, function, use case, sector, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall bioinformatics market
  • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa.
  • To profile the key players and analyze their market share and core competencies2
  • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall bioinformatics market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

  • Company Information
  • Detailed analysis and profiling of additional market players (up to 5)

Product Analysis

  • Further breakdown of the Rest of Asia Pacific market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
  • Further breakdown of the Rest of Europe bioinformatics market into Russia, Austria, Finland, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries

TABLE OF CONTENTS

METHODOLOGY
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Bioinformatics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Bioinformatics Market

DMCA.com Protection Status
popup img